Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Immune thrombocytopenia (ITP) World Impact Survey(I-WISh): impact of ITP on health-related quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinically-suspected cast nephropathy: A retrospective, national, real-world study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cerebral Oxygen Metabolism in Adults with Sickle Cell Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sujith Samarasinghe
  • Katherine Clesham
  • Simona Iacobelli
  • Giulia Sbianchi
  • Cora Knol
  • Rose-Marie Hamladji
  • Gerard Socié
  • Mahmoud Aljurf
  • Mickey Koh
  • Henrik Sengeloev
  • Jean-Hugues Dalle
  • Stephen Robinson
  • Maria Teresa Van Lint
  • Constantijn J M Halkes
  • Dietrich Beelen
  • Ghulam J Mufti
  • John Snowden
  • Didier Blaise
  • Regis Peffault de Latour
  • Judith Marsh
  • Carlo Dufour
  • Antonio M Risitano
  • Severe Aplastic Anaemia Working Party of the EBMT
View graph of relations

We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti-thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14-0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35-0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA.

Original languageEnglish
JournalAmerican Journal of Hematology
Issue number1
Pages (from-to)80-86
Number of pages7
Publication statusPublished - 1 Jan 2019

ID: 56566007